Abbreviation: ARB, angiotensin II receptor blocker
EDARByclor® (azilsartan
medoxomil
/chlorthalidone)
Efficacy
Seize the power to help lower hypertension in your appropriate patients*
*Based on clinical trial data
vs Benicar HCT® (olmesartan
medoxomil-hydrochlorothiazide)1
EDARBYCLOR Head-to-Head Clinical Trial Results

EDARBYCLOR delivered statistically superior blood pressure control when compared to Benicar HCT® in a clinical study.1

Primary endpoint: clinic systolic blood pressure
(SBP) reduction at week 121
See Study Design

Week 12 reduction in mean SBP at each hour over 24 hours1

*This is a secondary endpoint. The study was not powered to dectect a difference in this endpoint; therefore, the ability to interpret the n value as significant is reduced.

See Study Design

Likelihood of reaching target SBP: <130 mm Hg at week 82
See Study Design
EDARBYCLOR Efficacy in Patient Subpopulations1Effective control across multiple patient populations1

EDARBYCLOR 40/25 mg was effective in treating multiple patient populations.1,3

Subgroup analyses of clinic SBP by baseline characteristics at week 121,†

†Treatment difference (95% confidence interval) at week 12 in clinic SBP reduction, mm Hg.

‡P<0.05.

Abbreviations: BMI, body mass index; eGFR, estimated glomerular filtration rate.

See Study Design

Demonstrated effectiveness in African American patients3

SBP reduction in the African American patient subgroup was evaluated in a secondary analysis. EDARBYCLOR 40/25 mg was effective in treating African American patients, usually a low-renin population.3

This is a subgroup analysis. The study was not powered to detect a difference in these subgroups; therefore, the ability to interpret the P value as significant is reduced.

SUBGROUP ANALYSIS SHOWED CLINIC SBP REDUCTION IN AFRICAN AMERICAN PATIENTS AT WEEK 123

Based on this post hoc subgroup analysis, EDARBYCLOR 40/25 mg delivered statistically superior clinic SBP reduction in self-identified Black patients with hypertension versus Benicar HCT 40/25 mg at week 12.

See Study Design
EDARBYCLOR SAFETY
AND TOLERABILITY
Demonstrated safety profile2

Safety was evaluated in more than 3900 patients.

Adverse events were generally mild and transient in clinical trials.
ADVERSE EVENTS2
Common adverse reactions that occurred in the 8-week factorial design trial in at least 2% of EDARBYCLOR-treated patients and that are greater than EDARBI or chlorthalidone
CLINICAL LABORATORY FINDINGS2
BL: baseline; Cr: creatinine; ULN: upper limit of normal
EDARBYCLOR RECOMMENDED DOSING
Benefits of 2 agents in a single tablet2

EDARBYCLOR is a once-daily oral medication that can help more of your patients achieve their BP goals.2

  • May be administered with or without food.
  • May be administered with other antihypertensive agents. 
  • Dose may be increased to 40/25 mg after 2 to 4 weeks as needed to achieve BP goals.
  • Correct volume depletion in patients prior to use.
  • Doses above maximum are probably not useful.
40/12.5 mg Once Daily
Starting dose
40/25 mg Once Daily
Maximal dose
Pills are not shown at actual size.

Powerful products meet powerful savings for patients

Your patients can get the prescription treatment they need at a cost they can afford with our comprehensive suite of savings programs. Help your patients reach their goals by finding the savings program that works for them.
View savings opportunities

EDARBI®
(azilsartan medoxomil)
When your patients need
single-agent power

EDARBI is an effective choice for a single-agent antihypertensive that delivers superior SBP control. EDARBI may be used as a monotherapy or in combination with other antihypertensive agents.4
Learn about EDARBi
edarbi logo

1. Cushman WC, Bakris GL, White WB, et al. Azilsartan medoxomil plus chlorthalidone reduces blood pressure more effectively than olmesartan plus hydrochlorothiazide in stage 2 systolic hypertension. Hypertension. 2012;60(2):310-318.
2. Edarbyclor [package insert]. Atlanta, GA: Arbor Pharmaceuticals, LLC; [2020].
3. Ferdinand KC, Bakris GL, Cushman WC, et al. Comparison of effectiveness of azilsartan medoxomil and olmesartan in Blacks versus whites with systemic hypertension. Am J Cardiol. 2018;122(9):1496-1505.
4. Edarbi [package insert]. Atlanta, GA: Arbor Pharmaceuticals, LLC; [2020].